Jo Fields1, Alison Richardson2, Jane Hopkinson3, Deborah Fenlon2. 1. Poole Hospital NHS Foundation Trust, Poole, Wales, United Kingdom; University of Southampton, Southampton, Wales, United Kingdom. Electronic address: Jo.fields@poole.nhs.uk. 2. University of Southampton, Southampton, Wales, United Kingdom; University Hospital Southampton NHS Foundation Trust, Southampton, Wales, United Kingdom. 3. Cardiff University, Cardiff, Wales, United Kingdom.
Abstract
CONTEXT: Women taking aromatase inhibitors as treatment for breast cancer commonly experience joint pain and stiffness (aromatase inhibitor-associated arthralgia [AIAA]), which can cause problems with adherence. There is evidence that exercise might be helpful, and Nordic walking could reduce joint pain compared to normal walking. OBJECTIVES: To determine the feasibility of a trial of Nordic walking as an exercise intervention for women with AIAA. METHODS: A feasibility study was carried out in a sample of women with AIAA using a randomized control design. Women were randomized to exercise (six-week supervised group Nordic walking training once per week with an increasing independent element, followed by six weeks 4 × 30 minutes/week independent Nordic walking); or enhanced usual care. Data were collected on recruitment, retention, exercise adherence, safety, and acceptability. The Brief Pain Inventory, GP Physical Activity Questionnaire, and biopsychosocial measures were completed at baseline, six and 12 weeks. RESULTS:Forty of 159 eligible women were recruited and attrition was 10%. There was no increased lymphedema and no long-term or serious injury. Adherence was >90% for weekly supervised group Nordic walking, and during independent Nordic walking, >80% women managed one to two Nordic walking sessions per week. From baseline to study end point, overall activity levels increased and pain reduced in both the intervention and control groups. CONCLUSION: Our findings indicate that women with AIAA are prepared to take up Nordic walking, complete a six-week supervised course and maintain increased activity levels over a 12-week period with no adverse effects.
RCT Entities:
CONTEXT: Women taking aromatase inhibitors as treatment for breast cancer commonly experience joint pain and stiffness (aromatase inhibitor-associated arthralgia [AIAA]), which can cause problems with adherence. There is evidence that exercise might be helpful, and Nordic walking could reduce joint pain compared to normal walking. OBJECTIVES: To determine the feasibility of a trial of Nordic walking as an exercise intervention for women with AIAA. METHODS: A feasibility study was carried out in a sample of women with AIAA using a randomized control design. Women were randomized to exercise (six-week supervised group Nordic walking training once per week with an increasing independent element, followed by six weeks 4 × 30 minutes/week independent Nordic walking); or enhanced usual care. Data were collected on recruitment, retention, exercise adherence, safety, and acceptability. The Brief Pain Inventory, GP Physical Activity Questionnaire, and biopsychosocial measures were completed at baseline, six and 12 weeks. RESULTS: Forty of 159 eligible women were recruited and attrition was 10%. There was no increased lymphedema and no long-term or serious injury. Adherence was >90% for weekly supervised group Nordic walking, and during independent Nordic walking, >80% women managed one to two Nordic walking sessions per week. From baseline to study end point, overall activity levels increased and pain reduced in both the intervention and control groups. CONCLUSION: Our findings indicate that women with AIAA are prepared to take up Nordic walking, complete a six-week supervised course and maintain increased activity levels over a 12-week period with no adverse effects.
Authors: Rebecca R Turner; Liz Steed; Helen Quirk; Rosa U Greasley; John M Saxton; Stephanie Jc Taylor; Derek J Rosario; Mohamed A Thaha; Liam Bourke Journal: Cochrane Database Syst Rev Date: 2018-09-19